Jonathan J. Chang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jonathan J. Chang has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Alex Avendano
Department of Biomedical Engineering, The Ohio State University, Columbus, OH 43210, USA
2 shared publications Gustavo Leone
Hollings Cancer Center and Department of Biochemistry & Molecular Biology, Medical University of South Carolina, Charleston, SC, USA
2 shared publications- Jonathan W. Song
Department of Mechanical and Aerospace Engineering, The Ohio State University, Columbus, OH 43210, USA
2 shared publications - Michael C. Ostrowski
Medical University of South Carolina
2 shared publications - Shuichi Takayama
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30332, USA
2 shared publications Andrea Gerken
Genomics Institute of the Novartis Research Foundation (GNF), San Diego, CA 92121, USA
1 shared publication
Latest Publications
- Open Access
- 31 January 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (7) , e2403043
Bioprinted Micro‐Clots for Kinetic Analysis of Endothelial Cell‐Mediated Fibrinolysis
Vascular hypo‐fibrinolysis is a historically underappreciated and understudied aspect of venous thromboembolism (VTE). This paper describes the development of a micro‐clot dissolution assay for quantifying the fibrinolytic capacity of endothelial cells – a key driver of VTE development. This assay is enabled using aqueous two‐phase systems (ATPS) to bioprint microscale fibrin clots over human umbilical vein endothelial cells (HUVECs). Importantly, these micro‐clots are orders of magnitude smaller than conventional fibrin constructs and allow HUVEC‐produced plasminogen activators to mediate visually quantifiable fibrinolysis. Using live‐cell time‐lapse imaging, micro‐clot dissolution by HUVECs is tracked, and fibrinolysis kinetics are quantified. The sensitivity of cell‐driven fibrinolysis to various stimuli is rapidly tested. The physiological relevance of this convenient high‐throughput assay is illustrated through treatments with lipopolysaccharide (LPS) and rosuvastatin that elicit anti‐ and pro‐fibrinolytic responses, respectively. Furthermore, treatment with baricitinib, an anti‐inflammatory therapeutic found to increase cardiovascular risks after market approval, provokes an anti‐fibrinolytic response – which highlights the potential role of endothelial cells in increasing VTE risk for patients receiving this drug. This endothelial cell fibrinolysis assay provides a high‐throughput and versatile drug testing platform – potentially allowing for early preclinical identification of therapeutics that may beneficially enhance or adversely impair endothelial fibrinolysis.
- 31 January 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (7) , e2403043
Open AccessBioprinted Micro‐Clots for Kinetic Analysis of Endothelial Cell‐Mediated Fibrinolysis
Vascular hypo‐fibrinolysis is a historically underappreciated and understudied aspect of venous thromboembolism (VTE). This paper describes the development of a micro‐clot dissolution assay for quantifying the fibrinolytic capacity of endothelial cells – a key driver of VTE development. This assay is enabled using aqueous two‐phase systems (ATPS) to bioprint microscale fibrin clots over human umbilical vein endothelial cells (HUVECs). Importantly, these micro‐clots are orders of magnitude smaller than conventional fibrin constructs and allow HUVEC‐produced plasminogen activators to mediate visually quantifiable fibrinolysis. Using live‐cell time‐lapse imaging, micro‐clot dissolution by HUVECs is tracked, and fibrinolysis kinetics are quantified. The sensitivity of cell‐driven fibrinolysis to various stimuli is rapidly tested. The physiological relevance of this convenient high‐throughput assay is illustrated through treatments with lipopolysaccharide (LPS) and rosuvastatin that elicit anti‐ and pro‐fibrinolytic responses, respectively. Furthermore, treatment with baricitinib, an anti‐inflammatory therapeutic found to increase cardiovascular risks after market approval, provokes an anti‐fibrinolytic response – which highlights the potential role of endothelial cells in increasing VTE risk for patients receiving this drug. This endothelial cell fibrinolysis assay provides a high‐throughput and versatile drug testing platform – potentially allowing for early preclinical identification of therapeutics that may beneficially enhance or adversely impair endothelial fibrinolysis.
- Open Access
- 22 November 2019
- Published by AIP Publishing in APL Bioengineering
- Vol. 3 (4) , 041503
Microphysiological systems modeling acute respiratory distress syndrome that capture mechanical force-induced injury-inflammation-repair
Complex in vitro models of the tissue microenvironment, termed microphysiological systems, have enormous potential to transform the process of discovering drugs and disease mechanisms. Such a paradigm shift is urgently needed in acute respiratory distress syndrome (ARDS), an acute lung condition with no successful therapies and a 40% mortality rate. Here, we consider how microphysiological systems could improve understanding of biological mechanisms driving ARDS and ultimately improve the success of therapies in clinical trials. We first discuss how microphysiological systems could explain the biological mechanisms underlying the segregation of ARDS patients into two clinically distinct phenotypes. Then, we contend that ARDS-mimetic microphysiological systems should recapitulate three critical aspects of the distal airway microenvironment, namely, mechanical force, inflammation, and fibrosis, and we review models that incorporate each of these aspects. Finally, we recognize the substantial challenges associated with combining inflammation, fibrosis, and/or mechanical force in microphysiological systems. Nevertheless, complex in vitro models are a novel paradigm for studying ARDS, and they could ultimately improve patient care.
- 22 November 2019
- Published by AIP Publishing in APL Bioengineering
- Vol. 3 (4) , 041503
Open AccessMicrophysiological systems modeling acute respiratory distress syndrome that capture mechanical force-induced injury-inflammation-repair
Complex in vitro models of the tissue microenvironment, termed microphysiological systems, have enormous potential to transform the process of discovering drugs and disease mechanisms. Such a paradigm shift is urgently needed in acute respiratory distress syndrome (ARDS), an acute lung condition with no successful therapies and a 40% mortality rate. Here, we consider how microphysiological systems could improve understanding of biological mechanisms driving ARDS and ultimately improve the success of therapies in clinical trials. We first discuss how microphysiological systems could explain the biological mechanisms underlying the segregation of ARDS patients into two clinically distinct phenotypes. Then, we contend that ARDS-mimetic microphysiological systems should recapitulate three critical aspects of the distal airway microenvironment, namely, mechanical force, inflammation, and fibrosis, and we review models that incorporate each of these aspects. Finally, we recognize the substantial challenges associated with combining inflammation, fibrosis, and/or mechanical force in microphysiological systems. Nevertheless, complex in vitro models are a novel paradigm for studying ARDS, and they could ultimately improve patient care.
- Open Access
- 26 October 2018
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 1 (5) , e201800190
Disruption of stromal hedgehog signaling initiates RNF5-mediated proteasomal degradation of PTEN and accelerates pancreatic tumor growth
The contribution of the tumor microenvironment to pancreatic ductal adenocarcinoma (PDAC) development is currently unclear. We therefore examined the consequences of disrupting paracrine Hedgehog (HH) signaling in PDAC stroma. Herein, we show that ablation of the key HH signaling geneSmoothened(Smo) in stromal fibroblasts led to increased proliferation of pancreatic tumor cells. Furthermore,Smodeletion resulted in proteasomal degradation of the tumor suppressor PTEN and activation of oncogenic protein kinase B (AKT) in fibroblasts. An unbiased proteomic screen identified RNF5 as a novel E3 ubiquitin ligase responsible for degradation of phosphatase and tensin homolog (PTEN) inSmo-null fibroblasts.Ring Finger Protein 5(Rnf5) knockdown or pharmacological inhibition of glycogen synthase kinase 3β (GSKβ), the kinase that marks PTEN for ubiquitination, rescued PTEN levels and reversed the oncogenic phenotype, identifying a new node of PTEN regulation. In PDAC patients, low stromal PTEN correlated with reduced overall survival. Mechanistically, PTEN loss decreased hydraulic permeability of the extracellular matrix, which was reversed by hyaluronidase treatment. These results define non-cell autonomous tumor-promoting mechanisms activated by disruption of the HH/PTEN axis and identifies new targets for restoring stromal tumor-suppressive functions.
- 26 October 2018
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 1 (5) , e201800190
Open AccessDisruption of stromal hedgehog signaling initiates RNF5-mediated proteasomal degradation of PTEN and accelerates pancreatic tumor growth
The contribution of the tumor microenvironment to pancreatic ductal adenocarcinoma (PDAC) development is currently unclear. We therefore examined the consequences of disrupting paracrine Hedgehog (HH) signaling in PDAC stroma. Herein, we show that ablation of the key HH signaling geneSmoothened(Smo) in stromal fibroblasts led to increased proliferation of pancreatic tumor cells. Furthermore,Smodeletion resulted in proteasomal degradation of the tumor suppressor PTEN and activation of oncogenic protein kinase B (AKT) in fibroblasts. An unbiased proteomic screen identified RNF5 as a novel E3 ubiquitin ligase responsible for degradation of phosphatase and tensin homolog (PTEN) inSmo-null fibroblasts.Ring Finger Protein 5(Rnf5) knockdown or pharmacological inhibition of glycogen synthase kinase 3β (GSKβ), the kinase that marks PTEN for ubiquitination, rescued PTEN levels and reversed the oncogenic phenotype, identifying a new node of PTEN regulation. In PDAC patients, low stromal PTEN correlated with reduced overall survival. Mechanistically, PTEN loss decreased hydraulic permeability of the extracellular matrix, which was reversed by hyaluronidase treatment. These results define non-cell autonomous tumor-promoting mechanisms activated by disruption of the HH/PTEN axis and identifies new targets for restoring stromal tumor-suppressive functions.
- 1 October 2008
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 18 (19) , 5255-5258
Discovery and biological evaluation of benzo[a]carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptor
- 1 October 2008
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 18 (19) , 5255-5258
Discovery and biological evaluation of benzo[a]carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptor